Related Experiment Video
Updated: Aug 13, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Current treatment and future directions in heart failure
Gretchen Wells1, William C Little
1Cardiology Section, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA.
Insights
Current heart failure treatments targeting neurohormonal systems show benefits, but mortality remains high. New research is exploring other pathophysiological pathways to improve outcomes for heart failure patients.
Area of Science:
- Cardiology
- Pathophysiology
- Pharmacology
Background:
- Neurohormonal system activation is a key factor in congestive heart failure pathophysiology.
- Angiotensin-converting-enzyme inhibitors and beta blockers have proven benefits in reducing morbidity and mortality.
- Despite current standard treatments, heart failure mortality rates remain unacceptably high.
Purpose of the Study:
- To review the current understanding of heart failure pathophysiology.
- To highlight the limitations of existing neurohormonal blockade therapies.
- To emphasize the need for investigating novel pathophysiological mechanisms and therapeutic targets.
Main Methods:
- Review of recent clinical trials and research findings in heart failure.
- Analysis of the established benefits of angiotensin-converting-enzyme inhibitors and beta blockers.
- Discussion of emerging research into alternative pathophysiological pathways.
Main Results:
- Established efficacy of angiotensin-converting-enzyme inhibitors and beta blockers in heart failure management.
- Persistent high mortality rates despite guideline-directed medical therapy.
- Identification of the need to explore additional pathophysiological mechanisms beyond neurohormonal blockade.
Conclusions:
- Standard therapies for heart failure, including angiotensin-converting-enzyme inhibitors and beta blockers, are crucial but insufficient.
- Further research into alternative pathophysiological pathways is essential for developing more effective treatments.
- Interruption of newly identified pathways holds promise for reducing heart failure mortality.
Abstract:
Recent research in the pathophysiology of congestive heart failure has focused on the blockade of neurohormonal systems. Large clinical trials have clearly demonstrated morbidity and mortality benefits of angiotensin-converting-enzyme inhibitors and beta blockers. Indeed, all patients with heart failure should be treated with these agents unless there is a specific contraindication otherwise. Despite this treatment, however, mortality from heart failure remains high. Current investigation is now focused on other pathophysiological mechanisms and the interruption of these pathways.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy V: Interprofessional Care

